Strategic collaborations and partnering are a fantastic way to access new markets. 42 of the top 100 pharma companies are headquartered in Europe and this only scratches the surface.

The European pharma sector is much more diverse than the common perception of dominant Big Pharmas. Europe has a fascinating collection of Mid-sized pharma companies with unique therapeutic area focus, deep geographical expertise and a need to collaborate. These European MidPharmas provide non-EU companies with an excellent route into the European market but why are they such good partners?

75% of the European MidPharmas are privately held and therefore do not have the access to capital that some of the larger companies have. This makes it challenging for them to pursue game changing innovation and as such they manage and grow their portfolios inorganically, which is becoming harder as the cost of mergers and acquisitions rises.

The benefit of their need to grow inorganically through collaborations is your assets are of tangible benefit to the them, so are nurtured with an attention that can be absent in larger companies. This is amplified by their therapeutic focus, geographic expertise and deep understanding of customer needs, which make them excellent partners to support non-EU companies in Europe.

Through our experience in the European pharma sector we have helped many companies access strategic collaborations in Europe by understanding their assets and needs, assessing partner profiles to ensure optimum fit and leveraging our unique network to facilitate meaningful business conversations.

Contact us to understand how we could help you find the ideal partner in Europe:

Discover how you can establish your commercial footprint in Europe

Download our White Paper to explore European entry from a US Biotech’s perspective

Establishing a commercial footprint in Europe is a great approach for companies with global ambition. The European market presents unique challenges, which non-EU companies may not have experienced, so is often seen as a complex environment to enter.

Although there are challenges to enter the market the rewards are there for companies who understand their markets and utilise European expertise to navigate them, such as Gilead which is now one of the world’s biggest pharma companies.

Many US and Asian companies enlist local European support to traverse the landscape which combines centralised EU bodies and individual countries, who have their own unique processes for regulation, market access and pricing, to produce a diverse market with individual needs.

There are many steps to self-commercialisation and they require deep expertise in the European market to execute:

• Opportunity assessment

• Go-To-Market model

• Assess and design launch planning

• Affiliate establishment

• Ongoing regional support

Contact us to understand how we could help you establish yourself in Europe:

Discover how strategic collaborations and partnerships can be an alternative route into Europe

Download our White Paper to explore European entry from a US Biotech’s perspective

We developed a set of R&D platforms that enhanced competitiveness in a strategically vital therapeutic area.

To achieve this, we:

benchmarked resource allocation, capabilities, and development strategies against best-in-class peers;

defined a clear set of creative strategic options, before evaluating risk, investment, and required organisational capabilities for each;

successfully guided the organisation through strategy selection and co-creation of implementation roadmap.

We delivered a go-to-market strategy for a medical device company with an innovative technology platform.

To achieve this, we:

analysed market size, product potential, partnering options, and competitive landscape through primary and secondary research;

demonstrated a clear direction for product development through designing a clear, workable commercialisation roadmap;

ensured that senior management and the Board of Directors were aligned on the new commercial strategy.

We helped transform a company with diverse clinical and commercial assets into a focused, specialty pharma.

To achieve this, we:

built a bespoke business model based on analysis of the client’s portfolio and commercial strengths;

identified viable alternative growth scenarios,  and evaluated risk and value implications of each;

worked with the Board of Directors to agree a major corporate transformation plan.

Newsletter Signup